John Fesko, President and Chief Business Officer of Natera, Inc. (NASDAQ: NTRA), sold a total of 1,712 shares of the companys common stock in transactions executed on January 27 and January 28, 2026. The two trades generated proceeds totaling $409,127.
On January 27, Fesko sold 784 shares at $240.5313 per share. After that sale he directly owned 176,468 shares of Natera. The following day, on January 28, he sold 928 shares at $237.6624 per share, leaving him with 175,540 shares directly owned.
Company filings indicate the disposition of shares was undertaken to satisfy tax obligations arising from the vesting of Restricted Stock Units (RSUs). The transactions were placed within a pre-arranged 10b5-1 trading plan.
Natera, a genetic testing and diagnostics company, is currently valued at nearly $32 billion. According to InvestingPro data referenced in company materials, Nateras stock has risen about 64% over the past six months.
Investors monitoring Natera should note the companys next scheduled earnings release on March 4, 2026. In addition, InvestingPro provides further analysis on the company, including 11 supplementary insights in its Pro Research Report, which highlights metrics such as a financial health score and reported revenue growth of 38%.
Recent corporate updates provide context for investor attention. Natera reported preliminary fourth-quarter 2025 results that showed expected revenue growth of nearly 40% year-over-year, outpacing analyst expectations. Test volume for that quarter increased by roughly 17%.
On the equity research front, Canaccord Genuity has maintained a Buy rating on Natera and set a price target of $285.00.
Clinical and product developments have continued in parallel. Natera has finished enrollment in the ACES-EMB trial, which is evaluating whether the Prospera Heart test can serve as a noninvasive substitute for biopsies to monitor heart transplant rejection. The trial enrolled more than 300 participants across 17 U.S. transplant centers.
The company also announced a collaboration with Exelixis to run a phase 3 trial in colorectal cancer patients that will use Nateras Signatera test to identify candidates with molecular residual disease. Separately, Natera introduced a new AI model intended to improve cancer recurrence risk assessment through enhanced molecular residual disease testing.
In addition, Natera plans to present results from its EXPAND trial at the Society for Maternal-Fetal Medicine meeting; that presentation will focus on fetal genetic screening.
These operational updates - spanning revenue, test volume, clinical trials and diagnostic model development - form the backdrop to the insider transactions. The sales by Fesko were described in filings as tax-driven and executed under an established trading plan, and do not change the companies disclosed remaining insider ownership figures.
Shareholders and market watchers may weigh the insider sales alongside the companys recent preliminary financials and clinical milestones as they prepare for the March 4 earnings announcement.